{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"095-664-846-312-728","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"095-664-846-312-728"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11697,"type":"PATENT","title":"Oregon Health and Science University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2948,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8352,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: oregon uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2661
Search Applicants and Owners separately: oregon uni*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 2661
administering to the subject a composition comprising an effective amount of DRα1-MOG-35-55 and a pharmaceutically acceptable carrier."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising administering the composition to the subject after the onset of ischemia."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition comprises a dose of 20-25 mg/kg of DRα1-MOG-35-55."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the composition is formulated for subcutaneous or intravenous administration."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the subject is human."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the DRα1-MOG-35-55 comprises the amino acid sequence of SEQ ID NO: 1."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A composition for use in treating ischemic stroke in a subject comprising an effective amount of DRα1-MOG-35-55 and a pharmaceutically acceptable carrier."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 7, comprising a dose of 4-25 mg/kg of DRα1-MOG-35-55."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 7, formulated for subcutaneous or intravenous administration."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The composition of claim 7, wherein the DRα1-MOG-35-55 comprises the amino acid sequence of SEQ ID NO: 1."],"number":10,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}